Xófigo vs 177Lu-labelled anti-PSMA
Introduction - PCa (Prostate Cancer) is a disease with a high incidence rate. Xofigo (223Ra dichloride) is a medicine indicated for patients with this disease in the metastatic phase specifically, symptomatic bone metastases. 177Lu-anti-PSMA represents a set of promising molecules in radioimmunother...
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | conferenceObject |
| Language: | eng |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10400.21/7789 |
| Country: | Portugal |
| Oai: | oai:repositorio.ipl.pt:10400.21/7789 |